Scandion Oncology (SCOL) | Spotlight

Home

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-: 0.42
%: 6,30%
Latest: 7.09
High: 7.09
Low: 6.45
Volume: 69 220
Turnover (SEK): 466 176
Value (MSEK): 84,4

Board

CEO

Nils Brünner

Chairman Of The Board

Jørgen Bardenfleth

Board

Carl Borrebäck
Christian Vinding Thomsen
Peter Høngaard
Thomas Feldthus

News

2019-08-05 16:06:12 First day of trading in TO 1 in Scandion Oncology
2019-07-26 08:44:29 Spotlight: Market Notice 210/19 - Last day of trading in Scandion Oncology A/S"s BTU
2019-07-25 12:12:45 Last day of trading in BTU in Scandion Oncology
2019-07-12 10:34:52 Significantly oversubscribed rights issue in Scandion Oncology
2019-06-27 14:12:44 Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trial

Show More

News agencies

2019-07-12 11:04:54 Finwire: Scandion Oncologys nyemission blev overtegnet
2019-07-12 10:41:52 Finwire: Scandion Oncologys nyemission blev övertecknad
2019-06-27 14:22:52 Finwire: Scandion Oncology utser fyra kliniker i Danmark för fas II-studien med SCO-101
2019-06-26 11:44:04 Finwire: Scandion Oncology har produceret de første tabletter af SCO-101
2019-06-26 10:13:16 Finwire: Scandion Oncology har tillverkat SCO-101 i tablettform

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Key Numbers

*Compiled data from Millistream

Upcoming reports

2019-08-22 Delårsrapport 2019-Q2
2019-11-19 Delårsrapport 2019-Q3

Annual reports, prospectus etc.